Sanford-Burnham Medical Research Institute

Sanford Consortium, Takeda partner in $10M innovation alliance

Thursday, June 11, 2015

The Sanford Consortium for Regenerative Medicine in La Jolla, Calif., and Takeda Pharmaceutical have agreed to establish a $10 million, five-year innovation alliance that would advance each organization’s research missions. Specifically, translational research and proof-of-concepts research projects will be identified and generated with an ultimate goal of delivering innovative therapeutic products to patients.

[Read More]

Eli Lilly, Sanford-Burnham collaborate to investigate immunological therapies

Friday, May 15, 2015

Eli Lilly and Sanford-Burnham Medical Research Institute, a nonprofit medical research institute based in Florida, are collaborating to discover and develop immunological therapies. The company will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren’s Syndrome, inflammatory bowel disease and other autoimmune disorders.

[Read More]

Sanford-Burnham, Pfizer collaborate

Thursday, August 15, 2013

Sanford-Burnham Medical Research Institute has signed a three-year collaboration agreement with Pfizer to identify therapeutic targets for preventing and treating complications of obesity and diabetes. The team will utilize novel screening tools including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering therapeutic strategies for reducing insulin resistance in obesity and diabetes.

[Read More]